Form 4: Mineralys Director DiRocco Receives Equity Awards

Mineralys Therapeutics Director Derek DiRocco was granted 6,200 Restricted Stock Units and 8,300 stock options, which he holds for RA Capital Management funds.

Summary

• Derek DiRocco, a Director of Mineralys Therapeutics, Inc. (MLYS), was granted equity awards.
• On February 19, 2026, DiRocco acquired 6,200 Restricted Stock Units (RSUs) with a grant price of $0.
• On the same date, he acquired 8,300 stock options with an exercise price of $28.06.
• The RSUs are scheduled to vest in one annual installment following the grant date.
• The stock options are scheduled to vest in 12 substantially equal monthly installments following the grant date.
• DiRocco disclaims beneficial ownership of these RSUs and options, as they are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus III Fund, L.P., with any net proceeds offsetting advisory fees owed by these funds to RA Capital Management, L.P.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard director compensation and alignment of interests, though the beneficial ownership by RA Capital funds adds a layer of complexity.

Positives

• The grant of equity awards (RSUs and stock options) to a director aligns their interests with long-term shareholder value, even if beneficially owned by a third party.

Negatives

• No direct negatives identified in this transactional filing.

Risks

• No specific risks mentioned in this Form 4 filing.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology and pharmaceutical industry, aiming to incentivize long-term commitment and align interests with company performance. The beneficial ownership by RA Capital funds indicates a specific investment strategy where the director's compensation is channeled back to the fund, representing the institutional investor's stake.

Comparison to Industry Standards

• Granting equity awards to directors is a standard practice across publicly traded companies, particularly in the biotech sector, to align director incentives with shareholder value.
• The specific arrangement where the director holds the awards for the benefit of investment funds (RA Capital) is less common for individual directors but typical for representatives of institutional investors on a board, ensuring the fund's interests are represented.

Related Party Transactions

• Derek DiRocco, a director, holds the granted RSUs and stock options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus III Fund, L.P., with any net proceeds offsetting advisory fees owed by the funds to RA Capital Management, L.P.

Stakeholder Impact

• Shareholders: The grant of equity awards aligns the director's interests with shareholder value, although the beneficial ownership by RA Capital funds means the direct financial benefit accrues to those funds rather than the individual director.
• RA Capital Funds: The arrangement directly benefits RA Capital Healthcare Fund, L.P. and RA Capital Nexus III Fund, L.P. by offsetting advisory fees.

Next Steps

• The 6,200 RSUs will vest in one annual installment following the grant date of February 19, 2026.
• The 8,300 stock options will vest in 12 substantially equal monthly installments following the grant date of February 19, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice and does not provide new information that would significantly alter the investment thesis for Mineralys Therapeutics. The beneficial ownership arrangement with RA Capital funds is noted but does not change the fundamental outlook based solely on this filing.

Keywords

MLYS, Mineralys Therapeutics, Derek DiRocco, Form 4, RSU, Stock Option, Insider Transaction, Equity Grant, RA Capital